Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Monopar Therapeutics (MNPR) stocks in Canada

Learn how to easily invest in Monopar Therapeutics stocks.

Monopar Therapeutics is a biotechnology business based in the US. Monopar Therapeutics stocks (MNPR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.71 – a decrease of 5.07% over the previous week. Monopar Therapeutics employs 9 staff and has a market cap (total outstanding stock value) of $37.3 million.

How to buy shares in Monopar Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MNPR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Monopar Therapeutics stock price (NASDAQ:MNPR)

Use our graph to track the performance of MNPR stocks over time.

Monopar Therapeutics shares at a glance

Information last updated 2022-01-17.
Latest market close$2.81
52-week range$2.76 - $11.60
50-day moving average $4.04
200-day moving average $5.01
Wall St. target price$28.40
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.70

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Monopar Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Monopar Therapeutics price performance over time

Historical closes compared with the close of $2.81 from 2022-01-21

1 week (2022-01-14) -5.07%
1 month (2021-12-23) -15.87%
3 months (2021-10-22) -38.65%
6 months (2021-07-23) -49.37%
1 year (2021-01-22) -59.84%
2 years (2020-01-24) -82.97%
3 years (2019-01-20) N/A
5 years (2017-01-20) N/A

Monopar Therapeutics financials

Gross profit TTM $0
Return on assets TTM -26.76%
Return on equity TTM -44.11%
Profit margin 0%
Book value $1.69
Market capitalisation $37.3 million

TTM: trailing 12 months

Monopar Therapeutics share dividends

We're not expecting Monopar Therapeutics to pay a dividend over the next 12 months.

Monopar Therapeutics share price volatility

Over the last 12 months, Monopar Therapeutics's shares have ranged in value from as little as $2.76 up to $11.6. A popular way to gauge a stock's volatility is its "beta".

MNPR.US volatility(beta: 0.96)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Monopar Therapeutics's is 0.9609. This would suggest that Monopar Therapeutics's shares are less volatile than average (for this exchange).

Monopar Therapeutics overview

Monopar Therapeutics Inc. , a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a humanized monoclonal antibody for the treatment of advanced cancers and severe COVID-19 that is in preclinical stage. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. It also has a collaboration agreement with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in multiple types of cancer. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.

Stocks similar to Monopar Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site